Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, Inc., as indicated in the metadata) on April 17, 2009, covering events occurring on April 13, 2009. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific employee retention program:
- Total Cash Pool: $1,250,000 allocated for retention payments to certain employees and executive officers.
- Stock Option Exercise Price: $2.49 per share (closing price on April 13, 2009).
Material Changes
The primary material change is the approval of a new employee retention program by the Compensation Committee. This program includes:
- Cash Retention Payments: Paid in two installments (50% on October 13, 2009, and 50% on April 13, 2010), contingent on continued employment or a change of control.
- Stock Options: Granted to all employees, vesting 50% on January 13, 2010, and 50% on October 13, 2010.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, revenue outlook, or general management commentary regarding business strategy. The focus is strictly on the terms of the retention program. Notable contingencies include:
- Payments are conditional on the recipient remaining employed by Synta or a successor company.
- Accelerated payment of unvested retention amounts occurs if an employee is terminated without "cause" prior to April 13, 2010.
Named Executive Officer Awards
| Name | Title | Total Retention Payment | Stock Options (#) |
|---|---|---|---|
| Safi R. Bahcall, Ph.D. | President and CEO | $0 (Voluntarily declined) | 146,300 |
| Keith S. Ehrlich, C.P.A. | CFO | $49,000 | 30,870 |
| James G. Barsoum, Ph.D. | SVP, Research | $0 (Voluntarily declined) | 42,900 |
| Eric W. Jacobson, M.D. | SVP, Clinical Research & CMO | $60,400 | 47,112 |
| Keizo Koya, Ph.D. | SVP, Drug Development | $0 (Voluntarily declined) | 44,616 |
Investor Verification Checklist
- Verify the company name is Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc.
- Confirm the total cash liability of $1,250,000 and its impact on the company's cash position.
- Review the vesting schedule of the new stock options (Jan 2010 and Oct 2010) and the dilution impact.
- Note that the CEO and two SVPs voluntarily declined the cash portion of the retention package.
- Check subsequent filings for any changes in employment status that would trigger accelerated payments.